incrementalnew treatment
IL-18 binding protein (tadekinig alfa) completes phase II trial in AOSD
Adult-Onset Still's Disease →Summary
The first clinical trial targeting IL-18 directly in AOSD (Gabay et al. 2018) demonstrated a favorable safety profile and early signs of efficacy at both 80mg and 160mg doses. This proof-of-concept study validates IL-18 as a druggable target and opens a new therapeutic approach distinct from IL-1 and IL-6 blockade.
More from Adult-Onset Still's Disease
significantnew treatment
Anakinra confirmed superior to DMARDs in systemic AOSD: ANAKINRA-STILLS trial
landmarkDiagnostic advance
2023 ACR/EULAR classification criteria for Still's disease published
significantMechanism
Gasdermin D and pyroptosis established as central to AOSD cytokine storm
incrementalnew treatment
JAK inhibitors show early promise in refractory AOSD
ID: adult-onset-stills-disease-update-5Type: new_treatmentImpact: incremental